Dear Client,
As part of our ongoing commitment to ensuring the security of your online trading experience, we would like to inform you of our protocol for addressing any suspicious activities observed on your trading account.
Should you notice any irregularities or suspect unauthorized access to your account, we kindly request that you take immediate action by following the steps outlined below:
Send an EmailPlease send an email to stoptrade@acml.infrom your registered email ID. In the email, briefly outline the suspicious activity you have observed.
Phone Call Alternatively, you can call us at 07965081981 Ext: 4 from your registered mobile number. This will enable us to address your concerns promptly.
When contacting us, please ensure you provide the following details:
By providing this information, you enable us to swiftly investigate and take appropriate measures to safeguard your account.
Your security and peace of mind are of utmost importance to us,and we appreciate your cooperation in maintaining the integrity of your trading account.
Brooks Laboratories Ltd announced credit rating actions from multiple agencies, with CARE Ratings Limited upgrading its Long-term Bank Facilities to CARE BB+; Stable from CARE BB; Stable and its Short-term Bank Facilities to CARE A4+ from CARE A4, while maintaining the rating on Fund-based - LT-Cash Credit at CARE BB+; Stable and Non-fund-based - ST-BG/LC at CARE A4+, with a separate maintenance of CARE A4 on November 11, 2025, for Non-fund-based - ST-BG/LC, and CARE BB-; Stable and CARE BB-; Positive on prior dates of November 7, 2024, and October 31, 2023, respectively; CARE Ratings Ltd. also upgraded Long-term bank facilities to CARE BB+; Stable and Short-term bank facilities to CARE A4+ from CARE BB and CARE A4, respectively, noting a modest scale of operations at Rs 86.26 crore in FY26 and referencing instruments including Corporate Bonds and Debentures and Commercial Papers, alongside Guaranteed bank debt of Rs 116.77 crore and Outstanding CG exposure of Rs 48.15 crore, with a target revenue of ~Rs 150 crore in FY29; furthermore, CARE Ratings Limited (Care Edge Ratings) has assigned a Stable outlook to the Manufacturing Business in anticipation of a proposed demerger into Abridge Speciality Limited (ASL), with positive and negative sensitivity triggers based on TOI and PBILDT performance, while CareEdge Ratings clarified that its ratings represent opinions on the likelihood of timely payment.